Ralph Salvagno, MD
Chief Executive Officer
  • Orthopaedic Surgeon with 30 years of direct patient care experience
  • Developer of several patent pending biopharma technologies
Anton Leighton, MD
Founder and Chief Medical Officer
  • 25+ years of drug development experience, including US Head, Infectious Diseases and Inflammation at Roche (Nutley, NJ)
  • Successful clinical development consultant for biotech companies; including for COVID-19 drug development
Bruce Harmon
  • 40 years experience; CFO, director, and/or audit chairman of public and private companies
  • Has taken 15 companies public  - IPO to NASDAQ, SB-2 and reverse mergers
Stefan Lyne Oliver, PhD
Director of Research
  • Research scientist at Stanford University School of Medicine
  • More than 25 years of experience within biotechnology and academy setting

A Word from our CEO, Ralph Salvagno, MD

Our team at Dale Biotech recognizes the need for the best scientific minds to come together to tackle the current health crisis related to COVID-19.

We are also committed to using our expertise with Rhamnolipids to develop an oral formulation which is not only efficacious but also cost effective. Our experience with Rhamnolipids and our early research with niclosamide, has led us to a unique formulation that has the potential to not only treat early cases of COVID-19 but also could be used for prophylaxis against COVID-19 and other future viral threats.

Please join us , as an investor or as follower, and support our efforts to combat this worldwide pandemic.

Ralph T. Salvagno, MD

Thank You!